Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure: A Systematic Review

Journal of Cardiac Failure

Volumn 15, Issue 3, 2009, Pages 256-266

  Araújo, José Paulo ^a   Lourenço, Patricia ^a   Azevedo, Ana ^a,b   Friões, Fernando ^a   Rocha Gonçalves, Francisco ^a   Ferreira, António ^a   Bettencourt, Paulo ^a  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Heart failure; high sensitivity C reactive protein; inflammatory activation; myocardial infarction; prognosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN;

CARDIOVASCULAR RISK; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

C-REACTIVE PROTEIN; DISEASE PROGRESSION; HEART FAILURE; HUMANS; PROGNOSIS;

EID: 62749131218     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2008.10.030     Document Type: Review

References (86)

1. Levine B., Kalman J., Mayer L., et al. Elevated circulating levels of tumour necrosis factor in severe chronic heart failure. N Engl J Med 223 (1990) 236-241
2. Bozkurt B., Kribbs S., Clubb Jr. F.J., et al. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodelling in rats. Circulation 97 (1998) 1382-1391
3. Steele I.C., Nugent A.M., Maguire S., et al. Cytokine profile in chronic cardiac failure. Eur J Clin Invest 26 (1996) 1018-1022
4. Kubota T., McTiernan C.F., Frye C.S., et al. Dilated cardiomyopathy in transgenic mice with cardiac specific over expression of tumor necrosis factor-α. Circ Res 81 (1997) 627-635
5. Mann D.L. Mechanisms and models in heart failure: a combinatorial approach. Circulation 100 (1999) 999-1088
6. Paulus W.J. How are cytokines activated in heart failure?. Eur J Heart Fail 1 (1999) 309-312
7. Yamauchi-Takihara K., Ihara Y., Ogata A., et al. Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation 91 (1995) 1520-1524
8. Pasceri V., Willerson J.T., and Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 (2000) 2165-2168
9. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340 (1999) 115-126
10. D'Amore P.J. Evolution of C-reactive protein as a cardiac risk factor. Lab Med 36 (2005) 234-238
11. Kimberly M.M., Vesper H.W., Caudill S.P., et al. Standardization of immunoassays for measurement of high-sensitivity C-reactive protein. Clin Chem 49 (2003) 611-616
12. Ridker P.M. C-reactive protein and risks of future myocardial infarction and thrombotic stroke. Eur Heart J (1998) 191-193
13. Chew D.P., Bhatt D.L., Robbins M.A., et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary interventions. Circulation 104 (2001) 992-997
14. Strandberg T.E., and Tilvis R.S. C-reactive protein, cardiovascular risk factors and mortality in a prospective study in the elderly. Arterioscler Thromb Vasc Biol 20 (2000) 1057-1060
15. Anan F., Masaki T., Umeno Y., et al. Correlations of high-sensitivity C-reactive protein and atherosclerosis in Japanese type 2 diabetic patients. Eur J Endocrinol 157 (2007) 311-317
16. Werdan K. The activated immune system in congestive heart failure-from dropsy to the cytokine paradigm. J Intern Med 243 (1998) 87-92
17. Backes J.M., Howard P.A., and Moriarty P.M. Role of C-reactive protein in cardiovascular disease. Ann Pharmacother 38 (2004) 110-118
18. Matsumori A. Anti-inflammatory therapy for heart failure. Curr Opin Pharmacol 4 (2004) 171-176
19. Gottdiener J.S., Arnold A.M., Aurigemma G.P., et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 35 (2000) 1628-1637
20. Vasan R.S., Sullivan L.M., Roubenoff R., et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107 (2003) 1486-1491
21. Cesari M., Penninx B.W., Newman A.B., et al. Inflammatory markers and onset of cardiovascular events. Results from the Health ABC Study. Circulation 108 (2003) 2317-2
22. Kardys I., Knetsch A.M., Bleumink G.S., et al. C-reactive protein and risk of heart failure. The Rotterdam Study. Am Heart J 152 (2006) 514-520
23. Pietilla K.O., Harmoinen A.P., Jokinitty J., et al. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 17 (1996) 1345-1349
24. Berton G., Cordiano R., Palmieri R., et al. C-reactive protein in acute myocardial infarction: association with heart failure. Am Heart J 145 (2003) 1094-1101
25. Suleiman M., Aronson D., Reisner S.A., et al. Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. Am J Med 115 (2003) 695-701
26. Suleiman M., Khatib R., Agmon Y., et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction. Predictive role of C-reactive protein. J Am Coll Cardiol 47 (2006) 962-968
27. Scirica B.M., Morrow D.A., Cannon C.P., et al. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem 53 (2007) 1800-1807
28. Bursi F., Weston S.A., Killian J.M., et al. C-reactive protein and heart failure after myocardial infarction in the community. Am J Med 120 (2007) 616-622
29. Kavsak P.A., MacRae A.R., Newman A.M., et al. Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of long-term mortality and heart failure. Clin Biochem 40 (2007) 326-329
30. Hartford M., Wiklund O., Mattsson Hulten L., et al. C-reactive protein, interleukin-6, secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes. J Intern Med 262 (2007) 526-536
31. Mielniczuk L.M., Pfeffer M.A., Lewis E.F., et al. Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome. Am Heart J 155 (2008) 725-731
32. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein and B-type natriuretic peptide. Circulation 105 (2002) 1760-1763
33. Sabatine M.S., Morrow D.A., Jablonski K.A., et al. Prognostic significance of the Centers for disease control/American Heart Association high sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 115 (2007) 1528-1536
34. Williams E.S., Shah S.J., Ali S., et al. C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study. Eur J Heart Fail 10 (2008) 63-69
35. Campbell D.J., Woodward M., Chalmers J.P., et al. Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease. Hypertension 45 (2005) 69-74
36. Anand I.S., Latini R., Florea V.G., et al. C-reactive protein in heart failure. Prognostic value and the effect of valsartan. Circulation 112 (2005) 1428-1434
37. Yin W.H., Chen J.W., Jen H.L., et al. Independent prognostic value of elevated high sensitivity C-reactive protein in chronic heart failure. Am Heart J 147 (2004) 931-938
38. Xue C., Feng Y., Wo J., et al. Prognostic value of high-sensitivity C-reactive protein in patients with chronic heart failure. N Z Med J 119 (2006) U2314
39. Windram J.D., Loh P.H., Rigby A.S., et al. Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. Am Heart J 153 (2007) 1048-1055
40. Win W.H., Chen J.W., Feng A.N., et al. Multimarker approach to risk stratification among patients with advanced chronic heart failure. Clin Cardiol 30 (2007) 397-402
41. Tang W., Shrestha K., Lente F., et al. Usefulness of C-reactive protein and left ventricular diastolic performance for prognosis in patients with left ventricular systolic heart failure. Am J Cardiol 101 (2008) 370-373
42. Tanner H., Mohacsi P., Fuller-Bicer G.A., et al. Cytokine activation and disease progression in patients with stable moderate chronic heart failure. J Heart Lung Transplant 26 (2007) 622-629
43. Lamblin N., Mouquet F., Hennache B., et al. High-sensitivity c-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. Eur Heart J 26 (2005) 2245-2250
44. Chirinos J.A., Zambrano J.P., Chakko S., et al. Usefulness of C-reactive protein as an independent predictor of death in patients with ischaemic cardiomyophaty. Am J Cardiol 95 (2005) 88-90
45. Kaneko K., Kanda T., Yamauchi Y., et al. C-reactive protein in dilated cardiomyophaty. Cardiology 9 (1999) 215-219
46. Ronnow B.S., Reyna S.P., Muhlestein J.B., et al. C-reactive protein predicts death in patients with non-ischemic cardiomyophaty. Cardiology 104 (2005) 196-201
47. Lamarter F., and Grimm W. Predictive value of high-sensitivity C-reactive protein in patients with idiopathic dilated cardiomyophaty. PACE 28 (2005) 233-236
48. Ishikawa C., Tsutamoto T., Fujii M., et al. Prediction of mortality by high-sensitivity C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy. Circ J 70 (2006) 857-3
49. Alonso-Martinez J.L., Llorente-Diez B., Echegaray-Agara M., et al. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 4 (2002) 331-336
50. Mueller C., Laule-Kilian K., Christ A., et al. Inflammation and long-term mortality in acute congestive heart failure. Am Heart J 151 (2006) 845-850
51. Siirilä-waris K., Lassus J., Melin J., et al. FINN-AKVA study group. Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur Heart J 27 (2006) 3011-3017
52. Villacorta H., Masetto A.C., and Mesquita E.T. C-reactive protein: an inflammatory marker with prognostic value in patients with decompensated heart failure. Arq Bras Cardiol 88 (2007) 585-589
53. Michowitz Y., Arbel Y., Wexler D., et al. Predictive value of high sensitivity CRP in patients with diastolic heart failure. Int J Cardiol 125 (2008) 347-351
54. Frazier C., Alexander K., Newby L., et al. Associations of gender and aetiology with outcomes in heart failure with systolic dysfunction. A pooled analysis of 5 randomized trials. J Am Coll Cardiol 49 (2007) 1450-1458
55. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Canters for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
56. Hung J., Knuiman M.W., Divitini M.L., et al. Prevalence and risk factor correlates of elevated C-reactive protein in an adult Australian population. Am J Cardiol 101 (2008) 193-198
57. Lakoski S.G., Cushman M., Criqui M., et al. gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J 152 (2006) 593-598
58. Khera A., McGuire D.K., Murphy S.A., et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 46 (2005) 464-469
59. Hussey L.C., and Hardin S. Sex-related differences in heart failure. Heart Lung 32 (2003) 215-223
60. Panagiotakos D.B., Pitsavos C., Yannakoulia M., et al. The implication of obesity and central fat on markers of chronic inflammation: the ATTICA study. Atherosclerosis 183 (2005) 308-315
61. Pradhan A.D., Manson J.E., Rossouw J.E., et al. Inflammatory biomarkers, hormone replacement therapy and incident coronary heart disease: prospective analysis from the women's health initiative observational study. JAMA 288 (2002) 980-987
62. Kushner I., Broder M.L., and Karp D. Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction. J Clin Invest 61 (1978) 235-242
63. Heeschen C., Hamm C.W., Bruemmer J., et al. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. J Am Coll Cardiol 35 (2000) 1535-1542
64. James S.K., Armstrong P., Barnathan E., et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol 41 (2003) 916-924
65. Lindahl B, Toss H, Siegbahn A, et al Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 200:343:1139-1147.
66. Ferreiros E.R., Boissonet C.P., Pizarro R., Merletti P.F.G., Corrado G., Cagide A., et al. Independent prognostic value of elevated C-reactive protein in unstable angina Circulation 100 (1999) 1958-1963
67. Heinrich J., Schulte H., Schonfeld R., et al. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost 73 (1995) 374-378
68. Danesh J., Collins R., and Peto R. Chronic infections and coronary heart disease: is there a link?. Lancet 350 (1997) 430-436
69. Biasucci L.M., Vitelli A., Liuzzo G., et al. Elevated levels of interleukin-6 in unstable angina. Circulation 94 (1996) 874-877
70. Liuzzo G., Biasucci L.M., Rebuzzi A.G., et al. Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation 94 (1996) 2373-2380
71. Nian M., Lee P., Khaper N., et al. Inflammatory cytokines and postmyocardial infarction remodelling. Circ Res 94 (2004) 1543-1553
72. Venugopal S.K., Deveraj S., and Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 14 (2005) 33-37
73. Verma S., Wang C.H., Li S.H., et al. A self -fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106 (2002) 913-919
74. Griselli M., Herbert J., Hutchinson W.L., et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial. J Exp Med 190 (1999) 1733-1740
75. Elster S.K., Braunwald E., and Wood H.F. A study of C-reactive protein in the serum of patients with congestive heart failure. Am Heart J 51 (1956) 533-541
76. Clark D.J., Cleman M.W., Pfau S.E., et al. Serum complement activation in congestive heart failure. Am Heart J 141 (2001) 684-690
77. Anker S.D., and von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 90 (2004) 464-470
78. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
79. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
80. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
81. Pepys M.B., Hirschfield G.M., Tennents G.A., et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440 (2006) 1271-21
82. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007) 2248-2261
83. Investigators G.I.S.S.I.-H.F. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double blind, placebo-controlled trial. Lancet (2008)
84. Rauchhaus M., Coats A.J., and Anker S.D. The endotoxin-lipoprotein hypothesis. Lancet 356 (2000) 930-933
85. Morrow D.A., Cannon C.P., Jesse R.L., et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 115 (2007) e365-e375
86. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation 116 (2007) e99-e109